```html

Quasi‑Neurological Migraine: A Complete Medical Guide

Overview

Quasi‑neurological migraine (QNM) is a term used by neurologists to describe a subset of migraine attacks that feature prominent neurological symptoms—such as visual disturbances, sensory changes, or language problems—without the classic aura that defines “migraine with aura.” The name reflects its position between typical migraine and true neurological disease.

QNM most often affects:

• Women ages 20‑45 (approximately 3 : 1 female‑to‑male ratio)
• Individuals with a personal or family history of migraine
• People who experience frequent migraine attacks (≥ 8 per month)

Prevalence estimates vary because QNM is not always coded as a separate condition. International studies suggest that 5‑10 % of all migraine sufferers display quasi‑neurological features, translating to roughly 12‑24 million adults worldwide (World Health Organization, 2022).

Symptoms

Symptoms can differ from one episode to another, but a typical QNM attack includes the following elements:

Headache Characteristics

• Pulsating or throbbing pain – usually unilateral but can become bilateral.
• Moderate to severe intensity – often 6–8 on a 0‑10 pain scale.
• Duration – 4–72 hours if untreated.
• Worsening with physical activity – such as climbing stairs.

Quasi‑Neurological Features (appear before or during the headache)

• Visual disturbances – shimmering lights, “zig‑zag” lines, blind spots, or temporary loss of vision in one eye.
• Sensory changes – tingling or numbness in the face, arms, or legs (often unilateral).
• Language or speech difficulties – transient word‑finding problems (aphasia) or slurred speech.
• Vertigo or disequilibrium – a sensation of spinning or imbalance lasting minutes to hours.
• Auditory phenomena – ringing in the ears (tinnitus) or muffled hearing.
• Motor weakness – rare, brief weakness affecting one limb (often mistaken for a stroke).

Associated Symptoms

• Nausea or vomiting
• Photophobia (sensitivity to light)
• Phonophobia (sensitivity to sound)
• Neck stiffness or pain
• Fatigue after the attack (post‑drome)

Causes and Risk Factors

Underlying Pathophysiology

While the exact cause of QNM is still being researched, it shares the same neurovascular cascade as classic migraine:

1. Cortical spreading depression (CSD) – a wave of neuronal depolarization that spreads across the cerebral cortex, triggering aura‑like symptoms.
2. Trigeminovascular activation – release of vasoactive neuropeptides (e.g., CGRP, substance P) causing dilation of meningeal vessels and pain.
3. Central sensitization – heightened responsiveness of pain pathways, leading to prolonged headache and sensory symptoms.

In QNM, the CSD may involve regions that control language, sensation, or balance, creating the “quasi‑neurological” picture without full‑blown aura.

Risk Factors

• Female sex and hormonal fluctuations (menstruation, pregnancy, menopause)
• Family history of migraine (first‑degree relative)
• Age 20‑45 (peak incidence)
• Personal history of migraine with aura
• High stress levels or poor sleep hygiene
• Trigger exposure (caffeine, alcohol, bright lights, strong odors)
• Comorbid conditions – anxiety, depression, and hypertension increase the likelihood of QNM.

Diagnosis

Diagnosing QNM relies on a detailed clinical history and exclusion of other neurological disorders.

Clinical Interview

• Characterization of headache (location, quality, intensity, duration)
• Timeline of neurological symptoms relative to the headache
• Frequency of attacks and known triggers
• Family and personal migraine history

Physical & Neurological Examination

During a symptom‑free interval, the exam is usually normal. However, a focused exam can help rule out stroke, seizure, or demyelinating disease.

Diagnostic Tests (used to exclude other conditions)

• Magnetic Resonance Imaging (MRI) with and without contrast – rules out structural lesions, tumors, or demyelination.
• Magnetic Resonance Angiography (MRA) or CT Angiography – evaluates for vascular malformations.
• Electroencephalogram (EEG) – performed if seizures are suspected.
• Blood work – CBC, electrolytes, thyroid panel, and inflammatory markers if systemic disease is a concern.

Diagnostic Criteria (adapted from ICHD‑3)

To meet the definition of QNM, a patient must have:

1. At least five headache attacks fulfilling criteria 1–4.
2. Headache lasting 4‑72 h, with at least two of the following: unilateral location, pulsating quality, moderate/severe intensity, aggravation by routine physical activity.
3. Presence of at least one “quasi‑neurological” symptom (visual, sensory, speech, vertigo) that does not fully meet the aura criteria (e.g., shorter duration, atypical pattern).
4. Exclusion of alternative diagnoses by appropriate imaging/lab studies.

Treatment Options

Acute Management (to stop or lessen an ongoing attack)

• NSAIDs (e.g., ibuprofen 400‑600 mg PO q6‑8 h) – first‑line for mild‑moderate attacks.
• Triptans – sumatriptan 6 mg subcutaneous or 50‑100 mg oral; effective in 70‑80 % of migraineurs, especially when taken early (<30 min of symptom onset).
• Anti‑emetics – metoclopramide 10 mg IV/PO for nausea and to improve triptan absorption.
• CGRP receptor antagonists – gepants (ubrogepant 50 mg PO) have shown rapid relief without vasoconstriction, useful for patients with cardiovascular risk.
• Neuromodulation – single‑pulse transcranial magnetic stimulation (sTMS) applied within 2 h of aura‑like symptoms can abort the attack in ~40 % of cases (Cranial Nerve Study, 2021).

Preventive Therapy (for ≥ 4 attacks/month or disabling attacks)

Medication Class	Examples	Typical Dose	Evidence
Beta‑blockers	Propranolol, Metoprolol	80‑160 mg/day	Effective in 45‑55 % (Cochrane Review, 2020)
Antiepileptics	Topiramate, Valproate	100‑200 mg/day (Topiramate)	Reduction ≥ 50 % in 40‑50 % of patients
Antidepressants	Amitriptyline, Venlafaxine	25‑75 mg/day	Helpful when comorbid depression exists
CGRP monoclonal antibodies	Erenumab, Fremanezumab	70 mg monthly (Erenumab)	≥ 60 % achieve ≥ 50 % reduction (NIH, 2022)
Onabotulinum toxin A	Botox®	155‑195 U across 31 sites	Approved for chronic migraine (>15 days/mo)

Lifestyle & Non‑pharmacologic Strategies

• Identify and avoid personal triggers (keep a migraine diary).
• Regular sleep schedule – 7‑9 h/night; avoid > 2 h of sleep variation.
• Hydration – ≥ 2 L water/day.
• Exercise – moderate aerobic activity 150 min/week reduces attack frequency.
• Stress‑reduction techniques: mindfulness, CBT, progressive muscle relaxation.
• Dietary measures – limit caffeine to <200 mg/day, avoid aged cheeses, processed meats, and artificial sweeteners.

Living with Quasi‑Neurological Migraine

Managing QNM is a continuous process that blends medical treatment with day‑to‑day adjustments.

Practical Tips

1. Carry a “migraine kit.” Include your rescue medication, anti‑emetic, a copy of your prescription, sunglasses, and a small snack.
2. Set up a quiet, dark rest area. Even brief sensory reduction can shorten an attack.
3. Use a migraine diary app. Record date, time, triggers, symptom pattern, and medication response; share with your clinician every 3‑6 months.
4. Communicate at work or school. A written plan can facilitate accommodations (flexible breaks, reduced screen time).
5. Plan for “post‑drome” fatigue. Schedule low‑key activities for the day after an attack.
6. Stay current on preventive injections or infusions. Missed doses can lead to rebound attacks.

Support Resources

• Migraine Research Foundation (MRF) – patient education webinars.
• American Headache Society – Find a certified headache specialist.
• Local support groups – in‑person or online communities (e.g., Migraine Buddy).

Prevention

Preventive measures aim to lower attack frequency and severity.

Primary Prevention

• Maintain stable hormone levels – discuss hormonal therapy with a gynecologist if menstrual migraines are dominant.
• Weight management – a BMI < 25 kg/m² is associated with a 20 % reduction in migraine days (CDC, 2021).
• Limit “over‑use” of acute meds – > 10 days/month of triptans can lead to medication‑overuse headache.

Secondary Prevention (after an attack)

• Early use of triptans or gepants within the first 30 minutes of aura‑like symptoms.
• Short‑course steroid burst (e.g., prednisone 40 mg daily for 3 days) may abort a cluster of attacks in refractory cases, but should be used sparingly.

Complications

If QNM is not adequately treated, several complications can arise:

• Medication‑overuse headache (MOH) – chronic daily headache due to frequent use of analgesics.
• Chronic migraine – ≥ 15 headache days per month for > 3 months.
• Psychiatric comorbidity – higher rates of depression and anxiety (up to 30 %).
• Reduced quality of life – work absenteeism, decreased productivity, and social isolation.
• Rarely, misdiagnosis of stroke leading to unnecessary anticoagulation or invasive procedures.

When to Seek Emergency Care

Timely evaluation can rule out life‑threatening conditions such as subarachnoid hemorrhage, cerebral venous sinus thrombosis, or acute stroke.

---

References

• Mayo Clinic. “Migraine.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/migraine-headache
• World Health Organization. “Burden of Migraine.” 2022.
• American Headache Society. “Guidelines for the Treatment of Migraine.” 2021.
• Goadsby PJ, et al. “CGRP monoclonal antibodies for migraine prevention.” Cochrane Database of Systematic Reviews, 2022.
• Silberstein SD. “Migraine pathophysiology and treatment.” Neurology, 2021.
• Huang J, et al. “Single‑pulse transcranial magnetic stimulation for acute migraine with aura.” Headache, 2021.
• CDC. “Adult Obesity Facts.” 2021.

```